Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.73 0.71 (5.91%) Market Cap: 558.63 Mil Enterprise Value: 452.90 Mil PE Ratio: 0 PB Ratio: 5.63 GF Score: 56/100

Y-mAbs Therapeutics Inc to Host Key Opinion Leader Webinar on DANYELZA® - Conference Call Transcript

Sep 23, 2021 / 04:00PM GMT
Release Date Price: $30.22 (+1.17%)
Sara Parigian
LifeSci Advisors, LLC - VP of KOL Strategy & Management

Good afternoon, and welcome to the Y-mAbs Therapeutics KOL Webinar on DANYELZA frontline and HITS data in high-risk neuroblastoma. At this time, all attendees are in a listen-only mode. A live verbal question-and-answer session will follow today's formal presentation. This webinar is not being recorded, and there will be no replay made available following the conclusion of today's event.

I would now like to turn the call over to your host, Thomas Gad, Chairman, Founder and President of Y-mAbs Therapeutics. Please go ahead, Thomas.

Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Chairman, President and Head of Business Development & Strategy

Thank you, Sara. Before we begin, let me just remind everyone that today contains -- today's discussion contains forward-looking statements as defined by the Reform Act of 1995, the disclaimers here. With that said, we are very pleased today to have Dr. Jaume Mora from Hospital Sant Joan de Deu in Barcelona, probably one of the biggest

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot